1016-P: Prescribing SGLT2 and GLP-1 for Patients with Type 2 Diabetes at Time of Discharge after MI Increases Their Likelihood of Having Active Prescriptions at One Year

Abstract

Intro: SGLT2 inhibitors (SGLT2) and GLP1 agonists (GLP1) both reduce major adverse cardiovascular events (MACE) in patients with T2D and MI. We characterize the pattern of prescriptions for these medications in an urban safety net teaching hospital which provided these medications to low income patients at nominal cost. Methods: Using the hospital EHR, we reviewed medication lists for patients with T2D who were hospitalized with type 1 MI between 2018-2019. Results: There were 178 patients with one-year follow-up data, of which 75 (42.1%) were uninsured. We summarized the distribution of diabetes therapies in Table 1. SGLT2 and GLP1 were prescribed in 39% and 8% of patients at 1-year, respectively. Likelihood of having an active SGLT2 prescription at 1-year was higher for patients prescribed it at discharge compared to those who were not (RR 2.6; 95% CI 1.9-3.4). Likelihood of having an active GLP1 prescription at 1-year was higher for patients prescribed it at discharge compared to those who were not (RR 10.9; 95% CI 4.9-24.5). Conclusions: Rates of prescription of MACE-reducing therapies (SGLT2 and GLP1) after MI are low compared to metformin and insulin, which have no proven MACE benefit. Prescribing SGLT2 and GLP1 at index discharge can significantly increase the likelihood that patients will be prescribed these medications one year later. Disclosure N.Sumarsono: None. S.Das: None. C.L.Malladi: None. A.A.Dweik: None. P.L.Della-penna: None. K.Geurink: None. C.Mathew: None. E.Moss: None. K.Peykova: None. L.Mack-boyd: None.